Overview

* Kiniksa Q2 2025 ARCALYST revenue grows 52% yr/yr to $156.8 mln

* Kiniksa initiates Phase 2/3 trial for KPL-387 in recurrent pericarditis

Outlook

* Kiniksa raises 2025 ARCALYST revenue guidance to $625-$640 mln

* Company expects KPL-387 Phase 2 trial data in second half of 2026

* Company expects annual cash flow to remain positive

Result Drivers

* ARCALYST PENETRATION - Expanded penetration in recurrent pericarditis market drives 52% yr/yr revenue growth

* PRESCRIBER GROWTH - Increase in both new and repeat prescribers supports ARCALYST sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $156.80

Product mln

Revenue

Q2 EPS $0.24

Q2 Net $17.83

Income mln

Q2 $136.64

Operatin mln

g

Expenses

Q2 $22.88

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International PLC ( KNSA ) is $40.00, about 32.4% above its July 28 closing price of $27.04

* The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 33 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)